DiaMedica Therapeutics (NASDAQ:DMAC) Earns “Buy” Rating from HC Wainwright

DiaMedica Therapeutics (NASDAQ:DMAC)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $7.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 74.56% from the stock’s previous close.

Separately, Oppenheimer reissued an “outperform” rating and issued a $6.00 price target on shares of DiaMedica Therapeutics in a report on Friday, August 16th.

DiaMedica Therapeutics Stock Down 2.7 %

DMAC stock opened at $4.01 on Friday. The business has a 50 day moving average of $4.30 and a 200-day moving average of $3.58. The firm has a market cap of $171.43 million, a PE ratio of -7.16 and a beta of 1.46. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $4.95.

Institutional Trading of DiaMedica Therapeutics

Hedge funds have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in DiaMedica Therapeutics in the 3rd quarter worth about $40,000. Magnolia Capital Advisors LLC purchased a new position in shares of DiaMedica Therapeutics in the second quarter worth about $87,000. Blue Trust Inc. bought a new stake in shares of DiaMedica Therapeutics in the third quarter valued at approximately $185,000. Geode Capital Management LLC lifted its stake in shares of DiaMedica Therapeutics by 29.6% during the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after buying an additional 70,070 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of DiaMedica Therapeutics by 26.3% during the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after buying an additional 211,351 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.